NDA 217159 · Ayrmid Pharma
Aphexda
Motixafortide Acetate · Subcutaneous
NovelOrphanCDER novel approval, Sep 8, 2023: To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 8, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
1 Phase 3, 5 recruiting
FAERS reports
102
11 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 15, 2026.
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- APHEXDA · MOTIXAFORTIDE ACETATE EQ 62MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Motixafortide" as an intervention, any sponsor and status, largest first.
- Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaActive, not recruiting
Columbia UniversityAcademic, hospital or other
NCT04543071 · 118 participants (planned) · Start Nov 9, 2020 · Primary completion Jun 2028
Drug: Motixafortide; Cemiplimab and 2 more · For: Pancreatic Cancer; Adenocarcinoma of the Pancreas; Adenocarcinoma
Sites: Boston, Massachusetts; New York, New York; Providence, Rhode Island · 5 sites in all
Emory UniversityAcademic, hospital or other
NCT07101445 · 94 participants (planned) · Start Sep 24, 2025 · Primary completion Dec 31, 2026
Drug: Acetaminophen; Dexamethasone and 6 more · For: Multiple Myeloma
Sites: Atlanta, Georgia
- Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsPivotal-lookingRecruiting
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT06514508 · 60 participants (planned) · Start Dec 1, 2025 · Primary completion Sep 11, 2026
Drug: Motixafortide+G-CSF; Placebo+G-CSF · For: Multiple Myeloma
Sites: Beijing, China; Harbin, China
- Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy SubjectsCompleted
BioLineRx, Ltd.Industry
NCT05293171 · 38 participants · Start Jun 11, 2021 · Primary completion Jun 1, 2022
Drug: 1.25 mg/kg BL-8040 + BL-8040-matching placebo; 2 mg/kg BL-8040 and 2 more · For: Healthy Subjects
Sites: Phoenix, Arizona
- Gene Editing For Sickle Cell DiseaseRecruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT06506461 · 25 participants (planned) · Start Mar 21, 2025 · Primary completion Dec 2029
Drug: Plerixafor; Busulfan and 2 more · For: Sickle Cell Disease
Sites: Memphis, Tennessee
St. Jude Children's Research HospitalAcademic, hospital or other
NCT06442761 · 20 participants (planned) · Start Nov 14, 2024 · Primary completion Jan 2028
Drug: Motixafortide · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Bethesda, Maryland; Memphis, Tennessee
Washington University School of MedicineAcademic, hospital or other
NCT06547112 · 20 participants · Start Oct 31, 2024 · Primary completion Jul 23, 2025
Drug: Motixafortide; G-CSF · For: Multiple Myeloma
Sites: St Louis, Missouri
Washington University School of MedicineAcademic, hospital or other
NCT05618301 · 10 participants · Start Jul 7, 2023 · Primary completion Jun 24, 2025
Drug: Motixafortide; Natalizumab · For: Sickle Cell Disease
Sites: St Louis, Missouri
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain40
- pruritus26
- urticaria20
- flushing16
- rash12
- injection site erythema11
- paraesthesia10
- injection site pruritus9
- injection site reaction9
- hypersensitivity7
- discomfort6
- injection site swelling6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 66 |
| 2025 | 18 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Aphexda (Motixafortide Acetate) · HCPCS J2277
2024 spending
$923K
Beneficiaries
60
69 claims
Per beneficiary
$15,390
2024 ASP limit $25.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $923,386 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- WBC Growth Factors: ASCO Guideline Update.
Gyawali B, Bohlke K, Dickter JK, et al. · J Clin Oncol 2026 · Practice Guideline, Systematic Review
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Crees ZD, Rettig MP, Jayasinghe RG, et al. · Nat Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.
Manji GA, Chung V, Oh DY, et al. · Oncologist 2026 · Clinical Trial, Phase I, Randomized Controlled Trial
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Bockorny B, Macarulla T, Semenisty V, et al. · Clin Cancer Res 2021 · Clinical Trial, Phase II, Multicenter Study
- Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.
Ceran E, Jaramillo Segura S, Merbach AK, et al. · Blood 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.
Raufi AG, D'Souza EK, May MS, et al. · Nat Commun 2026 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Ayrmid Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.